Abstract:AbstractBACKGROUNDIn 1999, a World Health Organization (WHO) committee published histologic criteria for distinct thymoma entities (labeled as Type A, AB, B1, B2, B3 thymomas) and for the heterogeneous group of thymic carcinomas, collectively called Type C thymomas. Whether WHO‐defined histologic thymoma subtypes are of independent prognostic relevance has yet to be proved.METHODSTwo hundred thymomas from the Shanghai Chest Hospital with a mean follow‐up time of 15 years (range, 1–246 months) were studied for the relevance of WHO histologic subtype and other factors (stage, therapy, and myasthenia gravis [MG]) for survival.RESULTSIn order of frequency, 68 patients (34.0%) had Type AB, 39 (19.5%) had Type B2, 36 (18.0%) had Type C, 27 (13.5%) had Type B3, 17 (8.5%) had Type B1, and 8 (4.0%) had Type A thymoma. Five cases (2.5%) were rare thymomas not mentioned in the WHO classification. Survival data showed significant differences among the histologic subtypes (log rank test: P < 0.001). Among patients with Type A and AB thymomas, none died of tumor; of the Type B1 thymoma patients, only one (5.9%) died at 22 months. Type B2, B3, and C thymomas had a significantly worse prognosis with 5‐year survival rates of 75.0%, 70.0%, and 48.0%, respectively. Ninety‐six patients (48.0%) were in Masaoka Stage I, 26 (13.0%) were in Stage II, 65 (32.5%) were in Stage III, and 13 (6.5%) were in Stage IV. Stage was highly significant in predicting survival (log rank, test P < 0.001). The association between histologic subtype and invasive behavior (stage) was statistically significant (P < 0.001). However, histology was an independent predictive factor of survival in Stage I and II thymomas: Type B2, B3, and C thymomas had a worse prognosis than Type A, AB, and B1 thymomas (log rank test: P < 0.003). Thirty patients (15.0%) presented with MG. MG was significantly more frequent in Type B2 and B3 than in Type A, AB, and B1 thymomas (P < 0.01). On multivariate analysis, MG had no adverse effect on survival (P = 0.17). Radiation or chemotherapy improved patients' survival at 5 and 10 years in Type B2, B3, and C thymomas (log rank test: P < 0.003).CONCLUSIONSTumor stage is the most important determinant of survival in thymoma patients, but the WHO histologic subtype is an independent prognostic factor in Stage I and II thymomas, among which WHO Type A, AB, and B1 thymomas form a low‐risk group. Patients with high‐risk thymomas might profit from novel adjuvant radiochemotherapy regimens. Cancer 2002;95:420–9. © 2002 American Cancer Society.DOI 10.1002/cncr.10665

Combined thymoma(AB+B)--pathological diagnosis and clinical significance

Real-world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma

New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China.

Evaluation of a Histogenetic Classification for Thymomas

[Clinicopathological Significance of Grading on Thymic Epithelial Tumors].

[Clinicopathologic Analysis of 52 Cases of Thymic Epithelial Tumor].

Thymic Epithelial Tumors: A Clinicopathologic Study of 249 Cases from A Single Institution

New WHO Histologic Classification Predicts Prognosis of Thymic Epithelial Tumors

Transcriptomic difference of thymoma and thymic carcinoma

Clinicopathological Analysis of 241 Thymic Epithelial Tumors-Experience in the Shanghai Chest Hospital from 1997-2004.

Correlations of Novel Histological Classification of 82 Thymoma Patients to Their Clinical Characteristics and Prognosis

The Clinicopathological Significance of Thymic Epithelial Markers Expression in Thymoma and Thymic Carcinoma.

Correlations of the new WHO histological classification to the clinic characteristics of thymic epithelial tumours

Clinical analysis of 88 cases with combined small cell carcinoma

The Correlation Of The World Health Organization Histologic Classification Of Thymic Epithelial Tumors And Its Prognosis: A Clinicopathologic Study Of 108 Patients From China

Immunohistochemical Differentiation Between Type B3 Thymomas And Thymic Squamous Cell Carcinomas

Proteome Analysis and Tissue Array for Profiling Protein Markers Associated with Type B Thymoma Subclassification.

Thymoma and Thymic Carcinoma Associated with Multilocular Thymic Cyst: a Clinicopathologic Analysis of 18 Cases

Clinical and pathological aspects of thymic epithelial tumors

[Correlation of World Health Organization classification of thymic epithelial tumors to their CT features].

Mixed Thyroid Malignant Tumors